早期应用低分子肝素在急性心肌梗死患者溶栓治疗中的疗效观察

Effect of early use of low-molecular weight Heparin for thrombolytic therapy in patients with acute myocardial infarction

目的:探讨早期应用低分子肝素在急性心肌梗死患者溶栓治疗中的效果。方法:将我院收治的80例急性心肌梗死患者随机分为两组,观察组于入院后溶栓治疗前30～60 min予低分子肝素5 000 IU腹壁皮下注射,对照组于溶栓治疗后6 h给予低分子肝素5 000 IU腹壁皮下注射,对比两组冠脉再通及不良反应情况。结果:观察组冠脉再通率为85%,对照组再通率为65%,两组比较差异有统计学意义(P<0.05);观察组再通时间为(1.50±0.71)h,对照组为(2.10±0.92)h,差异有统计学意义(P<0.05);两组出血发生率比较差异无统计学意义(P>0.05)。结论:溶栓治疗前早期应用低分子肝素治疗对于提高急性心肌梗死患者冠脉再通率、缩短再通时间有积极意义,且安全性良好。

Objective： To explore the effect of early use of low-molecular weight Heparin（LMWH） for thrombolytic therapy in patients with acute myocardial infarction（AMI）.Methods： 80 patients with AMI were randomly divided into two groups,the 40 patients in the observation group were injected LMWH 5 000 IU and then were given Urokinase after 30-60 minutes of thrombolytic therapy,and the other 40 patients in the control group were given thrombolytic therapy first,and then injected LMWH 5 000 IU after 6 hours.The revascularization rate of coronary artery and the bleeding risk between the two groups were compared.Results： The revascularization rate in the observation group was significantly higher than that in the control group（85% vs 65%）（P0.05）.The revascularization time in the observation group [（1.50±0.71） h] was significantly shorter than that in the control group [（2.10±0.92） h]（P0.05）.The bleeding risk between the two groups had no significant difference（P0.05）.Conclusion： Early application of LMWH in AMI can improve the rates of recanalization,shorten the time of recanalization,this method is effective and safety.